Current oncology最新文献

{"title":"Abstracts of the 2024 Canadian Association of Medical Oncologists Annual Scientific Meeting.","authors":"Alexi Campbell, Sharlene Gill, Desirée Hao, Suneil Khanna, Erin Powell, Moira Rushton, Maryam Soleimani, Stephen Welch","doi":"10.3390/curroncol32020105","DOIUrl":"10.3390/curroncol32020105","url":null,"abstract":"<p><p>On behalf of the Canadian Association of Medical Oncologists, we are pleased to present the abstracts of the 2024 Annual Scientific Meeting. The CAMO Annual Scientific Meeting (ASM) took place from 24-26 October 2024 in an in-person event in Ottawa, ON. Twenty-four (24) abstracts were selected for presentation as oral presentations and poster presentations. Awards for the top three (3) abstracts were presented during the ASM; they have been marked as \"Award Recipient\". We congratulate all presenters on their research work and contribution.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward an Understanding of Cancer as an Issue of Social Justice: Perspectives and Implications for Oncology Nursing.","authors":"Tara C Horrill, Scott M Beck, Allison Wiens","doi":"10.3390/curroncol32020104","DOIUrl":"10.3390/curroncol32020104","url":null,"abstract":"<p><p>Within the fields of oncology practice and research, cancer has historically been and continues to be understood as primarily biologically produced and physiologically driven. This understanding is rooted in biomedicine, the dominant model of health and illness in the Western world. Yet, there is increasing evidence of inequities in cancer that are influenced by social and structural inequities. In this article, we propose that cancer-related inequities ought to be seen as issues of social justice, and, given nursing's longstanding commitments to social justice, they ought to be a priority for oncology nurses. Using a social justice lens, we highlight potential social injustices in the form of inequities in cancer outcomes and access to cancer care across the cancer continuum. Our intention is not to provide an exhaustive review of evidence, but to provide our perspective, adding to the dialogue surrounding health equity and cancer while shifting the narrative away from an understanding of cancer inequities as stemming from \"lifestyle\" and \"behavioural\" choices. We conclude by exploring the implications of considering cancer inequities as social injustices for nursing practice.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging Large Language Models for High-Quality Lay Summaries: Efficacy of ChatGPT-4 with Custom Prompts in a Consecutive Series of Prostate Cancer Manuscripts.","authors":"Emily Rinderknecht, Anna Schmelzer, Anton Kravchuk, Christopher Goßler, Johannes Breyer, Christian Gilfrich, Maximilian Burger, Simon Engelmann, Veronika Saberi, Clemens Kirschner, Dominik von Winning, Roman Mayr, Christian Wülfing, Hendrik Borgmann, Stephan Buse, Maximilian Haas, Matthias May","doi":"10.3390/curroncol32020102","DOIUrl":"10.3390/curroncol32020102","url":null,"abstract":"<p><p>Clear and accessible lay summaries are essential for enhancing the public understanding of scientific knowledge. This study aimed to evaluate whether ChatGPT-4 can generate high-quality lay summaries that are both accurate and comprehensible for prostate cancer research in <i>Current Oncology</i>. To achieve this, it systematically assessed ChatGPT-4's ability to summarize 80 prostate cancer articles published in the journal between July 2022 and June 2024 using two distinct prompt designs: a basic \"simple\" prompt and an enhanced \"extended\" prompt. Readability was assessed using established metrics, including the Flesch-Kincaid Reading Ease (FKRE), while content quality was evaluated with a 5-point Likert scale for alignment with source material. The extended prompt demonstrated significantly higher readability (median FKRE: 40.9 vs. 29.1, <i>p</i> < 0.001), better alignment with quality thresholds (86.2% vs. 47.5%, <i>p</i> < 0.001), and reduced the required reading level, making content more accessible. Both prompt designs produced content with high comprehensiveness (median Likert score: 5). This study highlights the critical role of tailored prompt engineering in optimizing large language models (LLMs) for medical communication. Limitations include the exclusive focus on prostate cancer, the use of predefined prompts without iterative refinement, and the absence of a direct comparison with human-crafted summaries. These findings underscore the transformative potential of LLMs like ChatGPT-4 to streamline the creation of lay summaries, reduce researchers' workload, and enhance public engagement. Future research should explore prompt variability, incorporate patient feedback, and extend applications across broader medical domains.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Requirements for Setting Up a Dedicated Structure for Adolescents and Young Adults with Cancer-A Systematic Review.","authors":"Lukas Rudolf von Rohr, Nadja Battanta, Cornelia Vetter, Katrin Scheinemann, Maria Otth","doi":"10.3390/curroncol32020101","DOIUrl":"10.3390/curroncol32020101","url":null,"abstract":"<p><p>Adolescents and young adults (AYAs), often defined as those aged 15-39 years, face unique challenges in oncology that are often unmet by conventional care models. This systematic review examines evidence on establishing dedicated AYA oncology units, focusing on logistical, infrastructural, and personnel-related recommendations. A PRISMA-guided search of PubMed (2000-2024) identified seven studies that emphasized early stakeholder involvement and collaboration between pediatric and adult oncology teams to ensure comprehensive care. Multidisciplinary teams (MDTs) of oncologists, nurses, and psychosocial support staff were highlighted as essential to address AYA patients' diverse needs. Care models varied, with some advocating consultation-based services and others supporting dedicated units. Priorities included increasing clinical trial enrollment, fertility counseling, and creating environments attuned to AYA patients' social and psychological needs. Key barriers included limited funding, institutional resistance, and inadequate pediatric/adult team collaboration. Despite progress, the lack of standardized guidelines and long-term data on AYA unit efficacy remains a challenge. Further research is required to develop outcome metrics, refine care models, and enhance survival and quality of life for AYA cancer patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy in the Transcortical and Transsylvian Approach in Insular High-Grade Gliomas: A Comparative Series of 58 Patients.","authors":"Alberto Morello, Francesca Rizzo, Andrea Gatto, Flavio Panico, Andrea Bianconi, Giulia Chiari, Daniele Armocida, Stefania Greco Crasto, Antonio Melcarne, Francesco Zenga, Roberta Rudà, Giovanni Morana, Diego Garbossa, Fabio Cofano","doi":"10.3390/curroncol32020098","DOIUrl":"10.3390/curroncol32020098","url":null,"abstract":"<p><p>Gliomas within the insular region represent one of the most challenging problems in neurosurgical oncology. There are two main surgical approaches to address the complex vascular network and functional areas around the insula: the transsylvian approach and the transcortical approach. In the literature, there is not a clear consensus on the best approach in terms of safety and efficacy. The purpose of this study is to evaluate the effectiveness of these approaches and to analyze prognostic factors on the natural history of insular gliomas. Patients with newly diagnosed high-grade insular gliomas who underwent surgery between January 2019 and June 2024 were analyzed. The series was analyzed according to the classification of Berger-Sanai and Yaşargil. The Karnofsky performance score (KPS), extent of resection (EOR), progression-free survival (PFS), and overall survival (OS) were considered the outcome measures. A total of 58 primary high-grade insular glioma patients were enrolled in this study. The IDH mutation was found in 13/58 (22.4%); specifically, 3/13 (23.1%) were grade 4, and 10/13 (76.9%) were grade 3. Furthermore, 40/58 patients (69%) underwent gross total resection (GTR), 15 patients (26%) subtotal resection, and 3 patients (5%) partial resection. Middle cerebral artery encasement negatively affected the OS. GTR, radiotherapy, KPS, and autonomous deambulation at a month after surgery positively affected the OS. The surgical approach used was transsylvian and transcortical in 11 and 47 cases, respectively. The comparison between the two different approaches did not display differences in terms of neurological deficits and OS (<i>p</i> > 0.05). The transcortical approach was related to the greater achievement of GTR (<i>p</i> = 0.031). According to the Berger-Sanai classification, the transcortical approach has higher EOR and postoperative KPS when the lesion is in zone III-IV (<i>p</i> = 0.029). Greater resection of insular gliomas can be achieved with an acceptable morbidity profile and is predictive of improved OS. Both the transsylvian and transcortical corridors to the insula are associated with low morbidity profiles. The transcortical approach with intraoperative mapping is more favorable for achieving greater EOR, particularly in gliomas within the inferior border of the Sylvian fissure.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Kampo Medicine Usage as Supportive Care During Anticancer Drug Treatment in Japanese Patients: A Nationwide Cohort Analysis from Fiscal Years 2015 to 2021.","authors":"Hiroaki Ohta, Takeo Yasu","doi":"10.3390/curroncol32020100","DOIUrl":"10.3390/curroncol32020100","url":null,"abstract":"<p><p>The adverse effects of anticancer drugs significantly impact the quality of life of patients undergoing chemotherapy, necessitating evidence-based supportive therapies. In Japan, Kampo medicines, traditional Japanese herbal therapies used for relief of various symptoms, have been widely used as complementary and alternative treatments for cancer, despite limited evidence regarding their efficacy and safety. Thus, we investigated the actual use of Kampo medicines as supportive care in patients undergoing anticancer drug treatment and evaluated the trends in prescription according to year. We analyzed 89,141 cancer drug therapy cases registered in the Japan Medical Data Center database between April 2014 and July 2022, excluding those with a history of Kampo medicine prescriptions before the first prescription of antineoplastic drugs. We assessed the trends in prescription according to sex, age group (<50, 50-74, and ≥75 years), and cancer type subgroup using the Cochran-Armitage trend test. Approximately 23.7% of patients were prescribed Kampo medicines during anticancer drug treatment. Since 2014, a decrease in the prescription of Kampo medicines during anticancer treatment has been observed regardless of sex, age, or cancer type. These findings suggest that recent negative reports on the efficacy and safety of Kampo medicines in cancer care may have influenced this trend.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome.","authors":"Abhishek Mahajan, Ujjwal Agarwal, Renuka M Ashtekar, Nivedita Chakrabarty, Richa Vaish, Vijay Maruti Patil, Vanita Noronha, Nandini Menon, Vasundhara Smriti, Jai Prakash Agarwal, Sarbani Ghosh-Laskar, Anil K D'Cruz, Pankaj Chaturvedi, Prathamesh Pai, Asawari Patil, Munita Bal, Swapnil Rane, Neha Mittal, Kumar Prabhash","doi":"10.3390/curroncol32020099","DOIUrl":"10.3390/curroncol32020099","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;According to the 8th edition of the American Joint Committee on Cancer (AJCC), involvement of the masticator space and infratemporal fossa (ITF) in oral cancers indicates advanced disease (T4b), which is often considered unresectable. Previous studies have shown that the extent of ITF involvement influences management and outcomes. Therefore, to optimize management, T4b disease should be subclassified based on ITF involvement. Notably, infranotch disease has a more favorable prognosis compared to supranotch disease. Our study also observed that certain subsets of high anterior retroantral ITF involvement may be operable with favorable clinical outcomes. This study aims to derive a new image-based compartmentalization of high ITF involvement and assess its impact on the management and outcomes of oral head and neck squamous cell carcinoma (HNSCC) patients with high ITF involvement.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;This retrospective observational study included 154 non-metastatic, upfront unresectable locally advanced HNSCC patients who were fit for induction neoadjuvant chemotherapy (NACT). ITF involvement was classified into distinct compartments, and detailed staging of the primary tumor (T) and regional nodes (Ns) was performed. Clinical data, including patient demographics, treatment received, and follow-up notes, were documented. Prognosis was assessed using survival metrics: event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). The ITF was categorized into the following compartments: compartment 1 (low ITF: medial pterygoid), compartment 2 (anterior high ITF: retroantral fat), compartment 3 (posterior high ITF), including 3a (paramandibular compartment: paramandibular fat/temporalis), 3b (muscle compartment: lateral pterygoid), and 3c (Perineural compartment: pterygopalatine fossa and pterygomaxillary fissure).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of the 154 cases, 142 (92%) were classified as T4b, with 63 (40.9%) having high ITF involvement and 79 (55.6%) having low ITF involvement. Twelve cases had T4a disease, which was deemed unresectable due to extensive nodal involvement. Subcompartmentalization of the 63 high ITF cases revealed 26 (41.2%) with compartment 2 involvement, 17 (26.9%) with compartment 3a involvement, 11 (17.4%) with compartment 3b involvement, and 9 (14%) with compartment 3c involvement. Disease progression following NACT was significantly higher in compartment 3c, which showed a poor response (&lt;i&gt;p&lt;/i&gt; = 0.007). Univariate analysis for PFS revealed similar outcomes for compartments 1 and 2 (&lt;i&gt;p&lt;/i&gt; = 0.692), while compartment 3 demonstrated poorer outcomes (&lt;i&gt;p&lt;/i&gt; = 0.033). Among thosehigh ITF involvement, compartment 3c had the worst PFS outcome (&lt;i&gt;p&lt;/i&gt; = 0.03).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Baseline imaging plays a critical role in guiding individualized treatment and predicting clinical outcomes. Low ITF involvement and disease limite","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Diagnostic Costs Using Hospital-Based Encounters in the Year Before Diagnosis for Canadian Patients with Malignant Central Nervous System Tumours Compared to Common Cancers.","authors":"Linwan Xu, Keyun Zhou, Yan Yuan, Emily V Walker","doi":"10.3390/curroncol32020096","DOIUrl":"10.3390/curroncol32020096","url":null,"abstract":"<p><p>Rare cancers pose significant diagnostic challenges, leading to more tests and higher healthcare expenditures (HEs). Understanding the financial implications of diagnosing rare cancers is crucial, particularly in Canada, where overall HEs are high (12% of the GDP in 2023). We investigated the pre-diagnostic hospital-based HE for patients with malignant central nervous system (CNS) tumours and compared it to patients with common cancers across Canadian provinces, using in-patient and ambulatory care data (2010-2014) from the Canadian Institute for Health Information. Pre-diagnostic HE was calculated as the change in total HE (in-patient and out-patient) during the 12 months before diagnosis, calculated as the HE within this period minus the average annual HE estimated over the two preceding years. Comparison groups included pediatric patients diagnosed with leukemia and patients aged over 15 diagnosed with colorectal cancer and lung cancer. We used quantile regression to estimate the adjusted effect of diagnosis with a CNS tumour on pre-diagnostic HE. The results indicated that HE for CNS patients was higher compared to those with common cancers. The top three factors contributing to HE variation were encounter type (in-patient/out-patient), province (Alberta/Ontario), and comorbidities (yes/no). Further investigation is warranted to understand the drivers of the cost differences.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of <i>BCR::ABL1/A337V</i> Can Be Effectively Overcome with Dasatinib Treatment.","authors":"Peter Batar, Gabriella Mezei, Arpad Illes","doi":"10.3390/curroncol32020097","DOIUrl":"10.3390/curroncol32020097","url":null,"abstract":"<p><p>Despite the groundbreaking success of tyrosine kinase inhibitor therapy, the management of chronic myeloid leukemia patients is often impaired by resistance due to specific point mutations in the <i>BCR::ABL1</i> oncogene. Upon classical ATP-competitive inhibitor treatment, these single nucleotide variants occur in the tyrosine kinase domain of ABL1. The novel allosteric BCR::ABL1 inhibitor asciminib was developed to treat CML patients alone or in combination to overcome or potentially prevent these treatment-emergent TKD mutations. Here, we present a case of a patient undergoing first-line asciminib therapy, and subsequently develop a specific <i>BCR::ABL1/A337V</i> point mutation, which resulted in asciminib resistance. Switching to second-line dasatinib treatment successfully overcame asciminib resistance and helped to achieve a deep molecular response. In case of treatment failures caused by single asciminib-specific point mutations, dasatinib therapy is a feasible choice.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging.","authors":"Abhishek Mahajan, Rajat Agarwal, Ujjwal Agarwal, Renuka M Ashtekar, Bharadwaj Komaravolu, Apparao Madiraju, Richa Vaish, Vivek Pawar, Vivek Punia, Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Nandini Menon, Kumar Prabhash, Pankaj Chaturvedi, Swapnil Rane, Priya Banwar, Sudeep Gupta","doi":"10.3390/curroncol32020095","DOIUrl":"10.3390/curroncol32020095","url":null,"abstract":"<p><strong>Background: </strong>Precise detection and characterization of pulmonary nodules on computed tomography (CT) is crucial for early diagnosis and management.</p><p><strong>Objectives: </strong>In this study, we propose the use of a deep learning-based algorithm to automatically detect pulmonary nodules in computed tomography (CT) scans. We evaluated the performance of the algorithm against the interpretation of radiologists to analyze the effectiveness of the algorithm.</p><p><strong>Materials and methods: </strong>The study was conducted in collaboration with a tertiary cancer center. We used a collection of public (LUNA) and private (tertiary cancer center) datasets to train our deep learning models. The sensitivity, the number of false positives per scan, and the FROC curve along with the CPM score were used to assess the performance of the deep learning algorithm by comparing the deep learning algorithm and the radiology predictions.</p><p><strong>Results: </strong>We evaluated 491 scans consisting of 5669 pulmonary nodules annotated by a radiologist from our hospital; our algorithm showed a sensitivity of 90% and with only 0.3 false positives per scan with a CPM score of 0.85. Apart from the nodule-wise performance, we also assessed the algorithm for the detection of patients containing true nodules where it achieved a sensitivity of 0.95 and specificity of 1.0 over 491 scans in the test cohort.</p><p><strong>Conclusions: </strong>Our multi-institutional validated deep learning-based algorithm can aid radiologists in confirming the detection of pulmonary nodules through computed tomography (CT) scans and identifying further abnormalities and can be used as an assistive tool. This will be helpful in national lung screening programs guiding early diagnosis and appropriate management.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 2","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11854842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}